Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel hepatitis B vaccines

W Jilg1

  • 1Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg, Germany.

Vaccine
|January 23, 1999
PubMed
Summary
This summary is machine-generated.

Hepatitis B vaccines are effective but improvements are needed. Research focuses on simplified schedules, enhanced immunogenicity, and overcoming potential immune escape strains for better hepatitis B prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time course of hepatitis E-specific antibodies in adults.

Journal of viral hepatitis·2016
Same author

Foodborne hepatitis A outbreak associated with bakery products in northern Germany, 2012.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2015
Same author

[Not Available].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2014
Same author

[Influenza].

Deutsche medizinische Wochenschrift (1946)·2013
Same author

Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.

Infection·2011
Same author

[Vaccinations].

Deutsche medizinische Wochenschrift (1946)·2011
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
See all related articles

Area of Science:

  • Vaccinology
  • Hepatology
  • Immunology

Background:

  • Current hepatitis B vaccines are safe and effective but require three doses, have a non-responder rate, and may face challenges from viral mutations.
  • Hepatitis B virus (HBV) infection remains a significant global health concern, necessitating continuous vaccine development.

Purpose of the Study:

  • To review current advancements and future directions in hepatitis B vaccine technology.
  • To address limitations of existing vaccines, including dosage, immunogenicity, and potential for immune evasion.

Main Methods:

  • Exploration of combined vaccine formulations for simplified infant immunization schedules.
  • Investigation of reduced-dose schedules and novel delivery systems like slow-release vaccines.
  • Development of recombinant vaccines incorporating preS1/preS2 regions or epitopes to enhance immunogenicity.

Related Experiment Videos

  • Consideration of alternative vaccine platforms such as bacterial expression and DNA vaccines.

    • Main Results:

    • Combined vaccines are under clinical evaluation, simplifying infant vaccination protocols.
    • Two-dose schedules and slow-release vaccine technologies show promise in reducing injection frequency.
    • Recombinant vaccines with expanded antigen components are in clinical trials, aiming for improved immune responses.
    • Novel approaches like oral and DNA vaccines are being explored for future hepatitis B prevention strategies.

    Conclusions:

    • Ongoing research aims to improve hepatitis B vaccine efficacy, compliance, and breadth of protection.
    • Future vaccine candidates hold the potential to overcome current limitations and contribute to hepatitis B elimination efforts.
    • Innovations in vaccine design and delivery are crucial for advancing global hepatitis B control.